Alpha-Centric ESG Research

Kyle Rudden

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):<ol>
<li>
COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).</li>
<li>
Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated <a href="https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html" target="_blank" rel="noopener">billions</a> to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.</li>
<li>
PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.</li>
</ol>

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):

COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).

Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated billions to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.

PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.


Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

The genetic testing industry in China is like a rising star – the favorable policy of precision medicine, the increasing industry scale and the long-term optimism about the growth potential from Chinese private equity firms and venture capitals have indicated tremendous opportunities.

The genetic testing industry in China is like a rising star – the favorable policy of precision medicine, the increasing industry scale and the long-term optimism about the growth potential from Chinese private equity firms and venture capitals have indicated tremendous opportunities.  

Insights on China Genetic Testing Industry

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Our outlook remains cautious as we continue to expect heightened volatility and a potential retest of the February 2018 lows over the next several weeks. Near-term we are monitoring for S&amp;P 500 support near 2,600 (i.e., the October low) and resistance near 2,817 or the 100- and 50-day moving averages. In today’s report we outline our current concerns along with developments that would cause us to become more constructive on the market. We also highlight attractive set ups within the Financials, Consumer Discretionary, and Health Care Sectors.

Our outlook remains cautious as we continue to expect heightened volatility and a potential retest of the February 2018 lows over the next several weeks. Near-term we are monitoring for S&amp;P 500 support near 2,600 (i.e., the October low) and resistance near 2,817 or the 100- and 50-day moving averages. In today’s report we outline our current concerns along with developments that would cause us to become more constructive on the market. We also highlight attractive set ups within the Financials, Consumer Discretionary, and Health Care Sectors.

U.S. Equity Strategy: Retest of October Lows Underway; Upgrading Financials

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

S&P 500: Outlook Constructive but Concerns Remain

Asia Long-Short PM/Analyst

Curtis Lehnert

The recent trade spat between the US and China has brought pain to the Singapore Tech sector.  Investors have indiscriminately dumped the sector with names trading down as much as 60% from recent highs.  It seems the expression, 'Don't throw the baby out with the bath water' has been forgotten.  I believe there are two or three stocks which standout as the 'babies' that have been thrown out in the cold as investors have rushed to sell first and ask questions later.  I'll admit it.  Technology stocks listed in Singapore don't really get a lot of people fired up.  Most of them are microcaps, have little analyst coverage and have never traded enough to get institutional investors interested.  So if you stop reading here, I won't be offended.  However, I do like situations that cause the majority of invetors not to bother.  It keeps competition modest.

The recent trade spat between the US and China has brought pain to the Singapore Tech sector.  Investors have indiscriminately dumped the sector with names trading down as much as 60% from recent highs.  It seems the expression, 'Don't throw the baby out with the bath water' has been forgotten.  I believe there are two or three stocks which standout as the 'babies' that have been thrown out in the cold as investors have rushed to sell first and ask questions later.  I'll admit it.  Technology stocks listed in Singapore don't really get a lot of people fired up.  Most of them are microcaps, have little analyst coverage and have never traded enough to get institutional investors interested.  So if you stop reading here, I won't be offended.  However, I do like situations that cause the majority of invetors not to bother.  It keeps competition modest.  

Venture Corp (VMS SP) And Other Singapore Tech Stocks: The Baby or the Bath Water? - Part 1

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific (TMO UN)

Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

Biden's recently-announced COVID-19 response plan suggests a number of investment themes. This Insight overviews the more significant of those...

Kyle Rudden

Insights on China Genetic Testing Industry

This article analyzed China genetic testing industry in the perspective of favorable policy, market potential, future trend, investment trend in...

Xinyao (Criss) Wang

U.S. Equity Strategy: Retest of October Lows Underway; Upgrading Financials

Our outlook remains cautious as we continue to expect heightened volatility and a potential retest of the February 2018 lows over the next several...

Vermilion Research

S&P 500: Outlook Constructive but Concerns Remain

As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...

Vermilion Research

Venture Corp (VMS SP) And Other Singapore Tech Stocks: The Baby or the Bath Water? - Part 1

The recent trade spat between the US and China has brought pain to the Singapore Tech sector. Investors have indiscriminately dumped the sector...

Curtis Lehnert

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)